HIV/AIDS, Viral Hepatitis, Sexually Transmitted Diseases, and Tuberculosis Five-Year Enacted Funding History

Bar chart showing funding beginning in fiscal year 2016 through fiscal year 2020 and amounts over time.

FY2016 - FY2020 funding reflects enacted1 amounts.
FY 2018 and FY 2019 enacted amounts are adjusted to reflect $7.222 million realignment from Tuberculosis in the HIV/AIDS, Viral Hepatitis, STI and TB Prevention account to Global Tuberculosis in the Global Health account.
FY 2019 and FY 2020 enacted amounts includes funding for Infectious Diseases and the Opioid Epidemic.

1 Enacted: The amount in the spending bill passed by both chambers of Congress and made into law.

HIV/AIDS, Viral Hepatitis, Sexually Transmitted Infections, and Tuberculosis Five-Year Enacted Funding History (dollars in thousands)

HIV/AIDS, Viral Hepatitis, Sexually Transmitted Infections, and Tuberculosis Five-Year Funding History (dollars in thousands)
Fiscal Year Enacted Amounts
FY 2016 $1,122,278
FY 2017 $1,117,278
FY 2018 $1,120,056
FY 2019 $1,125,056
FY 2020 $1,273,556

How is CDC funding used for HIV/AIDS, Viral Hepatitis, STIs, TB Prevention?

In FY 2020, the U.S. Congress enacted a spending bill that appropriated $1,127,556,000 to CDC to prevent and control HIV/AIDS, viral hepatitis, STIs, TB, infectious diseases and the opioid epidemic, and to promote adolescent and school health. The FY 2020 operating budget2 amount was $1,123,556,000:

  • Approximately 77% of the operating budget was awarded to state, tribal, local, and territorial health departments, community-based organizations, national organizations, academic institutions, and education agencies as grants and cooperative agreements.
  • Approximately 23% of the operating budget was spent on internal CDC resources that enable the nation’s response to infectious disease, including world-class laboratories, outbreak response, cutting-edge research, and technical assistance to health departments and community-based organizations.

These expenditures achieved measurable reduction in risk factors, illness, and death in communities at all levels of social status.

Domestic HIV/AIDS Prevention and Research, Viral Hepatitis, Sexually Transmitted Infections, and Tuberculosis FY 2020 Operating Level.

2The amount of funding available to an organization to obligate during the fiscal year to meet both routine business costs and program needs.

Domestic HIV/AIDS Prevention and Research, Viral Hepatitis, Sexually Transmitted Infections, and Tuberculosis FY2020 Operating Budget

Domestic HIV/AIDS Prevention and Research, Viral Hepatitis, Sexually Transmitted Infections, and Tuberculosis FY2017 Expenditures
Expenditure Type Amount
Extramural 77%
Intramural 23%
Total $1,123,556,000
Data Sources and Description

The funding data and state summaries provided were developed based on fiscal year (FY) 2020 actual spending. The data include actions awarded (i.e., obligated funds) domestically in federal FY 2020 (October 1, 2019 to September 30, 2020) from CDC’s annual appropriation. The funding data are categorized by CDC’s budget line as shown in the operating plans. The data represent a point in time and may not reflect CDC’s total appropriations in any given area.

Get Tested - Search for HIV Testing Services
Atlas Plus - Explore Interactive CDC Data
CDC 24/7 - Protecting America's Safety, Health, and Security
Page last reviewed: May 27, 2021